Table 1.
Inverse association of regular aspirin use with urinary TXB2 levels in cases and controls
| TXB2 | Aspirin use |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| All |
African American |
European American |
|||||||
| No, No. (%) | Yes, No. (%) | OR (95% CI) | No, No. (%) | Yes, No. (%) | OR (95% CI) | No, No. (%) | Yes, No. (%) | OR (95% CI) | |
| Cases | |||||||||
| Q1a | 72 (15.1) | 132 (27.9) | Refb | 35 (12.9) | 60 (29.6) | Refb | 37 (18.0) | 72 (26.7) | Refb |
| Q2 | 85 (17.9) | 107 (22.6) | 0.72 (0.46 to 1.14)b | 52 (19.2) | 46 (22.7) | 0.47 (0.24 to 0.83)b | 33 (16.1) | 61 (22.6) | 1.16 (0.58 to 2.30)b |
| Q3 | 128 (26.9) | 123 (26.0) | 0.47 (0.31 to 0.73)b | 74 (27.3) | 51 (25.1) | 0.31 (0.17 to 0.56)b | 54 (26.3) | 72 (26.7) | 0.70 (0.37 to 1.31)b |
| Q4 | 191 (40.1) | 111 (23.5) | 0.27 (0.18 to 0.41)b | 110 (40.6) | 46 (22.7) | 0.20 (0.11 to 0.36)b | 81 (39.5) | 65 (24.1) | 0.39 (0.21 to 0.70)b |
| Ptrend | <.001 | <.001 | <.001 | ||||||
| Controls | |||||||||
| Q1 | 71 (16.4) | 180 (31.8) | Refc | 38 (16.6) | 84 (35.4) | Refc | 33 (16.3) | 96 (29.1) | Refc |
| Q2 | 86 (19.9) | 163 (21.8) | 0.69 (0.46 to 1.04)c | 57 (24.9) | 75 (31.7) | 0.48 (0.27 to .84)c | 29 (14.3) | 88 (26.7) | 0.91 (0.49 to 1.68)c |
| Q3 | 129 (29.9) | 121 (21.3) | 0.31 (0.21 to 0.46)c | 66 (28.8) | 47 (19.8) | 0.27 (0.15 to 0.48)c | 63 (31.0) | 74 (22.4) | 0.32 (0.18 to 0.56)c |
| Q4 | 146 (33.8) | 103 (18.2) | 0.21 (0.14 to 0.32)c | 68 (29.7) | 31 (13.1) | 0.14 (0.08 to 0.27)c | 78 (38.4) | 72 (21.8) | 0.27 (0.15 to 0.47)c |
| Ptrend | <.001 | <.001 | <.001 | ||||||
Quartile (Q) cutoff points are 0.35, 0.505, and 0.738 ng TXB2/mg creatinine. CI = confidence interval; OR = odds ratio; Ref = reference.
Logistic regression analysis adjusted for age at study entry, body mass index (kg/m2), diabetes (yes or no), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes or no), self-reported race (not included in stratified analysis), disease stage (1 = stage I, 2 = stage IIA and IIB, 3 = stage III, 4 = stage IV), Gleason score (0 = Gleason ≤7 and 1 = Gleason >7), smoking history (never, former, current), and treatment (0 = none, 1 = surgery, 2 = radiation, 3 = hormone, 4 = combination).
Logistic regression analysis adjusted for age at study entry, BMI (kg/m2), diabetes (yes or no), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes or no), self-reported race (not included in stratified analysis), and smoking history (never, former, current).